Nifezzard

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nifezzard

Quick Facts

Property Description
Active Ingredient Nifedipine
Form Oral Tablets, Oral Capsules
Pharmacological Class Calcium Channel Blocker (CCB)
General Purpose Management of vascular resistance and blood flow
Origin Synthetic Organic Compound

What Type of Medicine is Nifezzard (Nifedipine)?

Nifezzard is a prescription-only medicine that contains the active ingredient Nifedipine, and belongs to the Calcium Channel Blocker (CCB) pharmacological class. Nifedipine is classified specifically as a Dihydropyridine derivative. This classification indicates the drug’s primary action is predominantly focused on the vascular system. Its general purpose as a cardiovascular agent is clinically recognized for assisting patients who require management of vascular constriction or high arterial pressure.

Composition, Form, and Origin of Nifezzard

The core composition of Nifezzard is the single active ingredient, Nifedipine, which is a synthetic organic compound derived from the Dihydropyridine structure. The medication is prepared for the oral route of administration and is typically presented in several dosage forms, including tablets and capsules. A key pharmaceutical distinction exists between immediate-release and extended-release forms, with the latter designed for sustained delivery of Nifedipine over a prolonged period. This controlled-release feature is clinically recognized for maintaining consistent therapeutic levels.

General Purpose: How Nifezzard Affects the Circulatory System

The primary function of Nifezzard is to promote vascular smooth muscle relaxation by modulating the movement of calcium ions. As a Calcium Channel Blocker, Nifedipine inhibits the entry of these ions into specific cell types, leading directly to the widening of arteries, a physiological effect known as vasodilation. This mechanism reduces the total peripheral resistance—the force that blood encounters in the circulatory system—thereby lowering systemic pressure and improving overall blood flow. This functional principle defines its core utility in easing the heart's workload and managing resistance-related circulatory issues.

Regulatory References

  1. Nifedipine - StatPearls - NCBI Bookshelf
  2. Nifedipine: MedlinePlus Drug Information

What side effects are possible with Nifezzard?

Possible Side Effects and Safety Information for Nifezzard

Nifezzard is associated with a risk profile that includes serious cardiovascular and gastrointestinal adverse events, as mandated by regulatory authorities like the U.S. Food and Drug Administration (FDA) for drugs of this class.


Adverse Reaction Scope

Key Adverse Reaction Categories:

  • Serious Cardiovascular (CV) Thrombotic Events: This includes an increased risk of myocardial infarction (heart attack) and stroke, which can be fatal. This risk can manifest early in treatment and may increase with longer use and higher doses.
  • Heart Failure: An increased risk of developing or worsening heart failure is documented.
  • Serious Gastrointestinal Adverse Events: Risk of bleeding, ulceration, and perforation of the stomach or intestines.

Serious and Clinically Significant Adverse Reactions:

  • Post-Myocardial Infarction Mortality: Patients treated with this class of medication following a first heart attack are more likely to die in the first year compared to those not treated.
  • System-Organ Classes Involved: Primarily the Cardiovascular System and the Gastrointestinal System.

Population-Specific Safety

Safety Considerations:

  • Patients with Pre-existing CV Disease: Individuals with established heart disease or risk factors for heart disease face a greater likelihood of adverse CV events, given their higher baseline risk.
  • Dose- and Exposure-Related Patterns: The risk of thrombotic events appears to be greater at higher doses and increases with longer duration of use of the drug.

Safety-Related Restrictions and Limitations:

  • To mitigate risk, Nifezzard should be used at the lowest effective dose for the shortest possible duration of time.
  • Caution is advised regarding the concurrent use of Nifezzard with low-dose aspirin taken for cardiovascular protection, as some drugs in this class may interfere with the anti-platelet effect of aspirin. Avoid taking multiple medicines containing this class of drug simultaneously.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Nifezzard (Nifedipine) is characterized by an exaggerated effect on the circulatory system, leading to severe hemodynamic instability. Officially documented manifestations include profound hypotension and the potential for shock. Other documented clinical signs are reflex tachycardia or bradycardia, confusion, lethargy, and respiratory depression. Regulatory data confirms that severe outcomes, such as myocardial infarction and death, are possible complications of excessive exposure.


When to Seek Urgent Medical Attention

In the event of a suspected or known overdose, immediate medical intervention is strictly required. Regulatory guidance mandates that individuals seek emergency medical attention right away and call the national Poison Help hotline. Ambulance transportation to an emergency department is recommended due to the potential for life-threatening complications.


Official Management and Monitoring

Treatment is classified as supportive, as no specific antidote is known. Official procedures dictate immediate active cardiovascular support, including the use of intravenous fluids and pressor agents. Specialized measures may include the judicious use of calcium infusion. Prolonged hospital monitoring is required for all cases, particularly following the ingestion of long-acting drug preparations, and clearance is expected to be prolonged in patients with impaired liver function.

Therapeutic Uses of Nifezzard

What Nifezzard Treats: Main Uses and Benefits

Nifezzard is commonly used to help with conditions presenting with systemic or localized discomfort across several cardiovascular and vascular domains.

This medication is generally applied in contexts involving temporary physiological imbalance, relevant for long-term management of high arterial pressure (Hypertension). It is also considered relevant in managing Angina Pectoris—managing chest pain associated with exertion or episodes of spontaneous arterial narrowing—and for addressing peripheral blood vessel constriction in conditions such as Raynaud's phenomenon.


Quick Facts: Relief for Vascular Symptoms

Property Description
Symptom Clusters Helps address symptom clusters related to chest discomfort and peripheral functional strain.
Condition Context Applied in conditions characterized by periods of heightened symptoms, including Hypertension and Angina.
Patient Benefit Supports the overall well-being and may assist with reducing the long-term risk of developing complications associated with high arterial pressure.

Long-term use is associated with providing support that helps ease the overall symptom burden over time, and may assist with reducing the long-term risk of developing complications such as a stroke or heart failure associated with this condition. The medication is relevant when symptoms interfere with routine activities, supports patients during episodes of heightened discomfort and provides supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview on Nifedipine

Eligibility and Restrictions for Use

Nifezzard (Nifedipine) is officially approved for use in adults (aged 18 and over). Regulatory documents define strict population eligibility rules, with several absolute contraindications that prohibit use.

The medicine must not be used in patients with known hypersensitivity to nifedipine or other dihydropyridines. It is also prohibited for patients experiencing cardiogenic shock, unstable angina pectoris, or during or within one month of an acute myocardial infarction. Additionally, co-administration with Rifampicin is strictly contraindicated.

Age-related eligibility is restricted: use in children and adolescents (under 18 years) is not established and not recommended due to insufficient data. While generally permitted for older adults, the immediate-release formulation should be avoided.

Use is generally not recommended during pregnancy (often contraindicated in regulatory labeling) or lactation. Conditional use requiring close monitoring is necessary for patients with severe hepatic impairment (liver problems), severe hypotension, and those with poor cardiac reserve. Furthermore, patients with specific hereditary metabolic problems or severe gastrointestinal obstructive disorders must avoid certain formulations.

What should I know about interactions with other medicines?

The metabolism of Nifezzard is primarily dependent on the Cytochrome P450 enzyme CYP3 A4. Interactions occur when co-administered substances either inhibit or induce this enzyme, or through additive pharmacodynamic effects on blood pressure.

Pharmacokinetic Interactions

Mechanism Interacting Products/Classes Resulting Action Classification
CYP3 A4 Inducers Rifampin, St. John's Wort, Phenytoin, Carbamazepine, Phenobarbital Significantly decreased Nifezzard plasma levels, leading to loss of therapeutic effect. Contraindicated/Avoid
CYP3 A4 Inhibitors Grapefruit Juice, certain Macrolide Antibiotics (e.g., Erythromycin), Antifungal Agents (e.g., Itraconazole), HIV Protease Inhibitors Increased Nifezzard plasma levels, enhancing the risk of side effects. Use with Caution/Monitoring Required

Pharmacodynamic and Other Interactions

  • Other Hypotensive Agents: Concomitant use with other medications that lower blood pressure, such as beta-blockers or alpha-blockers, can lead to severe or excessive hypotension due to additive effects. Close monitoring of blood pressure is essential.
  • Digoxin: Nifezzard has been associated with elevated serum concentrations of Digoxin, necessitating monitoring of Digoxin levels to prevent toxicity.
  • Anticoagulants: Increased prothrombin time has been observed in patients taking Coumarin anticoagulants (e.g., Warfarin); monitoring is required.

Food Restriction: The consumption of Grapefruit or Grapefruit Juice must be avoided for at least three days before and throughout treatment, as it is a potent inhibitor of CYP3 A4 and can significantly increase the drug's exposure.

Mechanism of Action

How Nifezzard works

Nifezzard functions as a dihydropyridine calcium ion influx inhibitor, engaging mechanisms that modulate smooth muscle and myocardial processes through calcium channel blockade.

It selectively targets the voltage-dependent L-type calcium channels found in peripheral vascular and cardiac smooth muscle cells. By binding to these channels, the drug suppresses the transmembrane influx of calcium ions, which is the essential molecular step required for cell contraction.

In vascular smooth muscle, this inhibition causes the arteries to relax and dilate (vasodilation). The resulting reduction in total peripheral resistance contributes to the dampening of heightened vascular tone and reduced afterload. In the coronary circulation, the same mechanism increases blood flow, thereby modulating myocardial oxygen supply by reducing the responsiveness of coronary smooth muscle to vasoconstrictor stimuli.

Dosage and Administration Information

Nifezzard is administered exclusively by the oral route in two primary forms: immediate-release (IR) capsules and extended-release (ER) tablets. The method and frequency of use depend on the specific formulation. Extended-release tablets are taken once daily with doses typically starting at 30 mg or 60 mg, with the maintenance range extending up to a maximum of 120 mg per day.

Conversely, immediate-release capsules require administration in divided doses three to four times per day. To ensure proper absorption and effectiveness, the extended-release tablets must be swallowed whole and must not be split, crushed, chewed, or otherwise divided, as this compromises the controlled delivery system. While immediate-release capsules can be taken with or without food, the ER tablet is generally recommended to be taken on an empty stomach. A critical procedural constraint is the mandatory avoidance of grapefruit and grapefruit juice while using Nifezzard.

Therapy is managed through a gradual dose adjustment process, where changes are typically implemented over a period of seven to fourteen days to assess the full response. For certain patient populations, such as those with hepatic impairment, caution is advised, and treatment should be initiated at the lowest available dose. Discontinuation of Nifezzard therapy requires a progressive reduction in dosage rather than abrupt cessation.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Nifezzard


Evidence for Use in High Arterial Pressure (Hypertension)

Nifezzard has been the subject of multiple studies, including Randomized Controlled Trials (RCTs) and long-term observational research. These studies were applied in research contexts involving patients with high arterial pressure, a condition characterized by functional limitations due to elevated systemic pressure. The main research focus was evaluated in to measure changes in blood pressure over time and to observe the occurrence of major cardiovascular events (heart attack, stroke).

Research examined sustained-release (SR) and extended-release (ER) formulations of the medicine. The findings describe patterns observed in the studies where use of these long-acting forms was studied for changes in blood pressure measurements, particularly when used alongside other anti-hypertensive medicines. Long-term studies monitored the occurrence of cardiovascular events, with data indicating patterns related to the rate of events when SR/ER formulations were part of a comprehensive treatment plan, though research does not determine whether an individual will respond similarly.


Evidence for Use in Angina Pectoris

This medicine has been studied for conditions involving periods of heightened symptoms, such as chronic stable angina and vasospastic angina (arterial narrowing). The studies explored outcomes related to physical discomfort, primarily by monitoring the weekly frequency and intensity of anginal episodes (chest pain). Researchers also used controlled stress testing to measure changes in outcomes reflecting daily functioning or activity level, such as how long patients could exercise before experiencing symptoms.

Studies report changes measured during the study period in the reported frequency of chest discomfort episodes. However, the evidence quality varies across studies based on the type of formulation tested. Some older meta-analyses of trials that used immediate-release (IR) Nifezzard were associated with findings of increased anginal episodes. More recent studies monitored patients using sustained-release formulations, where findings describe patterns observed in the studies when used to manage this condition characterized by fluctuating or episodic manifestations.


Key Areas of Research Uncertainty and Study Limitations

While a large amount of research is available, several limitations must be noted. One key distinction is the difference between the immediate-release (IR) and sustained-release (SR/ER) formulations, where the older IR studies were associated with patterns that led to concerns about rapid changes in drug levels. For many indications, the follow-up durations were limited to only a few weeks, meaning there is limited information for long-term outcomes or how well management is maintained over many years. The research highlights what is known — and what is still uncertain—especially regarding the comparative effect of Nifezzard versus all other available medicines.

Frequently Asked Questions (FAQ)

Common questions about Nifezzard (FAQ)


Q: What are the most commonly reported side effects of Nifezzard?

A: Official product information describes common side effects which include headache, dizziness, and a feeling of flushing or warmth. Patients may also commonly experience peripheral edema, which is swelling in the legs and ankles, as well as nausea or muscle cramps. This information reflects the side effects commonly reported in official studies.


Q: Can Nifezzard be taken if I am already taking over-the-counter pain relievers?

A: According to regulatory documentation, caution is advised regarding the use of over-the-counter (OTC) products that may raise blood pressure. This includes certain common products like non-steroidal anti-inflammatory drugs (NSAIDs) or various cough and cold remedies. Official guidelines recommend informing a healthcare provider about all OTC medications.


Q: What are the less common but serious side effects associated with Nifezzard?

A: Official safety information indicates that less common but serious adverse events are possible. These risks include the potential for myocardial infarction (heart attack) or stroke, and the development or worsening of angina or heart failure. Signs of a severe allergic reaction, such as swelling or difficulty breathing, require immediate medical attention.


Q: Are there specific warnings about Nifezzard use for older adults?

A: Regulatory documents advise that older adults should use Nifezzard with care, as they may be more likely to experience side effects. Specifically, the immediate-release (IR) formulation is generally cautioned against because of the potential for an excessive drop in blood pressure. Treatment should be tailored by a healthcare provider.


Q: What is the official risk classification for Nifezzard during pregnancy?

A: The official risk classification varies depending on the formulation; for instance, the immediate-release capsule has historically been classified as Pregnancy Category C. Official documents generally note that use during pregnancy is typically considered only if a healthcare provider determines the potential benefit outweighs the potential risk to the fetus. Use during pregnancy is usually not recommended.


Q: What happens if a person stops taking Nifezzard suddenly?

A: Official guidelines caution against stopping Nifezzard abruptly, as cessation is described as potentially leading to a worsening of the underlying condition, such as a sudden rise in blood pressure or increased frequency of angina. Any changes to treatment should involve a gradual, monitored dose reduction overseen by a healthcare professional.


Q: Does Nifezzard require any special monitoring, such as blood tests?

A: Regulatory documents state that patients taking Nifezzard may be required to have blood work checked regularly by their doctor. Specific monitoring is also necessary if Nifezzard is taken with certain other medications, such as Digoxin or Warfarin, to assess potential drug interactions.


Q: Are there warnings about Nifezzard use for people with liver disease?

A: The official label advises caution for individuals with liver problems, known as hepatic impairment. Because the drug may be processed more slowly by a damaged liver, it could potentially lead to higher drug levels in the body. Treatment is typically initiated at the lowest available dose.


Q: Does Nifezzard have any effect on heart rate or rhythm?

A: Studies and official product information indicate that Nifezzard may be associated with a fast or racing heartbeat, known as palpitations, as a common side effect. This is sometimes described as reflex tachycardia and occurs as a secondary response to the drug's blood pressure lowering effect.


Q: How long does it usually take for Nifezzard to start working?

A: The time it takes for Nifezzard to start working depends on the formulation taken. The immediate-release (IR) capsules are designed for a rapid onset of action. Conversely, the extended-release (ER) tablets are made to release the medicine slowly and provide stable levels over a full 24 hours.


Q: Is Nifezzard a medicine that must be taken long-term?

A: Official product information for the treatment of chronic conditions like high blood pressure indicates that long-term use may be necessary. The duration of therapy for high blood pressure management is determined by the prescribing physician.


Q: Does Nifezzard cause problems with sleep or insomnia?

A: According to regulatory documentation, sleeplessness or insomnia is listed as an uncommon adverse effect. Patients who experience new or worsening sleep issues should seek medical evaluation.


Q: Is Nifezzard known to cause changes in appetite or weight?

A: Regulatory documents report that changes in weight are possible. Unusual weight gain is listed as a potential side effect, which could be a sign of fluid retention (edema) or heart failure. Loss of appetite has also been reported in clinical contexts.


Q: What official documents describe the research evidence for Nifezzard?

A: The research evidence for Nifezzard, including data from Randomized Controlled Trials (RCTs), is available in the Clinical Studies section of the official FDA Prescribing Information. This detailed information is used by regulators and healthcare professionals to understand the drug's performance and safety profile.


Q: Is Nifezzard suitable for people with a known history of kidney issues?

A: Regulatory documents advise that people with kidney problems should use the drug with caution. The way the drug is absorbed and eliminated could be modified, meaning blood pressure may need to be monitored more closely under the guidance of a physician.


Q: Can Nifezzard affect a person's ability to drive or operate machinery?

A: Official warnings state that Nifezzard can affect a person's alertness or coordination due to effects like dizziness. Patients must avoid driving or operating heavy machinery until they understand how the medication affects them.


Q: What does the package insert say about alcohol consumption while on Nifezzard?

A: The package insert notes that it is unknown if drinking alcohol will directly affect Nifezzard or its main action. However, official warnings advise that consuming alcohol while on the drug may increase the risk of side effects such as dizziness or lightheadedness.


Q: Why do some people experience mild headaches when first starting Nifezzard?

A: Headache is listed in official documents as one of the most commonly reported side effects of Nifezzard. This effect is often related to the drug's primary action, which is vasodilation (the widening of arteries) to lower blood pressure.


Q: What is the usual duration of Nifezzard's effects after taking it?

A: The duration of the drug's effect is related to its half-life. The immediate-release (IR) form has a very short half-life, while the extended-release (ER) form has a longer half-life of around 7 hours to provide sustained effects for once-daily dosing.


Q: Is Nifezzard the same as its generic version?

A: Nifezzard is the brand name for the active ingredient Nifedipine. Regulatory bodies, such as the FDA, have determined that available generic versions containing Nifedipine are therapeutically equivalent to the brand-name product. This means they are expected to work the same way in the body.


Q: Can Nifezzard interact with common dietary supplements like vitamins?

A: Official guidelines recommend informing a healthcare provider about all prescription and over-the-counter medicines, as well as vitamins, minerals, or herbal products they are using. This is because some supplements can potentially interfere with the drug's metabolism.


Q: Is it normal to feel tired or fatigued after taking Nifezzard?

A: Tiredness, weakness, and fatigue are all listed as common side effects associated with Nifezzard use in the official adverse reaction reports. Patients experiencing persistent or severe fatigue should seek medical evaluation.


Q: What are the signs of a possible allergic reaction to Nifezzard?

A: Signs of a possible allergic reaction to Nifezzard can include skin issues like rash, hives, or itching. More severe signs, such as swelling of the face, lips, or tongue, and difficulty breathing, require immediate medical attention.


Q: How quickly is Nifezzard eliminated from the body?

A: The medicine is extensively processed by the liver and then quickly eliminated from the body. Regulatory documents state that 60% to 80% of the dose is excreted in the urine as water-soluble inactive compounds.


Q: Is Nifezzard a newer drug, or has it been available for a long time?

A: The active ingredient in Nifezzard, Nifedipine, was first approved by the FDA prior to 1982. This indicates that the medicine has been in use and studied for a long period of time.


Q: Can Nifezzard affect mental clarity, memory, or focus?

A: Official adverse effect reports mention that dizziness, lightheadedness, and mood changes have been reported by some patients. These central nervous system (CNS) effects may indirectly impact mental clarity, memory, or focus.


Q: What is the meaning of the warning about 'drug interactions' for Nifezzard?

A: The warning about 'drug interactions' means that combining Nifezzard with certain other medications or substances can change how the drug works. This can potentially increase the risk of side effects or reduce the intended effect of either medication, which is why close monitoring is often required.


Q: Where can I find the official prescribing information for Nifezzard?

A: The official, detailed prescribing information for Nifezzard can be found in the manufacturer's official FDA Prescribing Information document. This information is also typically available on regulatory websites like the DailyMed, which is maintained by the U.S. National Library of Medicine.


Q: What is the typical timeframe for a doctor to review a patient's use of Nifezzard?

A: Regulatory dosing instructions describe that dose adjustments for Nifezzard are typically implemented gradually, over a period of seven to fourteen days. This phased approach implies a necessary review by the doctor during or after this timeframe to assess the full therapeutic response.


Q: Are there any common laboratory tests that can be affected by taking Nifezzard?

A: Official documents caution that Nifezzard may affect the results of certain medical tests. Official documents state that patients must inform laboratory personnel or technicians that they are taking this medicine before any tests are performed.


Q: Is Nifezzard an antibiotic or an anti-inflammatory drug?

A: No. Official classification states that Nifezzard is a Calcium Channel Blocker (CCB). It is primarily used to manage conditions related to blood vessel tone and blood pressure, and it is not classified as an antibiotic or an anti-inflammatory drug.


Q: What is the research status of Nifezzard for other potential uses?

A: While Nifezzard is only officially approved for hypertension and angina, the drug has been studied for other potential uses, such as Raynaud's phenomenon. Official regulatory documents stress that these are off-label uses not approved by health authorities.


Q: Are there different strengths of Nifezzard tablets available?

A: Yes, Nifezzard is available in different strengths depending on the formulation. The immediate-release (IR) capsules are typically available in 10 mg and 20 mg strengths, while the extended-release (ER) tablets are typically available in 30 mg, 60 mg, and 90 mg strengths.

How should Nifezzard be stored and disposed of?

How to Store and Dispose of Nifezzard

This information reflects the official storage and disposal requirements defined in regulatory labeling.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically between 15 C and 30 C.
Protection Keep protected from light, moisture, and excessive humidity. Do not freeze.
Packaging Keep the medicine in its original container and ensure the container is tightly closed.
Safety The medicine must be stored out of the sight and reach of children.

Disposal Requirements

To dispose of unused or expired Nifezzard, utilize a drug take-back program (such as a pharmacy or authorized collector) when available. If a take-back program is not available, official instructions advise against flushing the medicine down the toilet. For household disposal, remove the medicine from its original container, mix it with an unappealing substance (like dirt or coffee grounds), seal the mixture in a bag, and place it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nifezzard found in:

A-Z Index: